On April 5, 2023, Stefani A. Wolff notified Nurix Therapeutics, Inc. of her decision to resign from her position as Chief Operating Officer and Executive Vice President of Product Development of Nurix, effective May 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.54 USD | +2.44% | -2.51% | +50.58% |
05-28 | Nurix Therapeutics, Inc. Appoints Paula G. O?Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer | CI |
05-20 | Nurix Therapeutics Names New Board Chair | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.58% | 922M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-0.55% | 21.83B | |
-10.88% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- NRIX Stock
- News Nurix Therapeutics, Inc.
- Stefani A. Wolff Resigns from Nurix Therapeutics, Inc. as Chief Operating Officer and Executive Vice President of Product Development